{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T14:31:20Z","timestamp":1774276280033,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-025-12592-1","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:43:51Z","timestamp":1744245831000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Economic burden of secondary progressive multiple sclerosis: DISCOVER study"],"prefix":"10.1186","volume":"25","author":[{"given":"Celia","family":"Oreja-Guevara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 E.","family":"Meca-Lallana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"G\u00f3mez-Est\u00e9vez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9-Ram\u00f3n","family":"Ara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1ngel Hern\u00e1ndez","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia Gracia","family":"Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Mar\u00eda Alonso","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bel\u00e9n Pilo","family":"de la Fuente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Llu\u00eds","family":"Rami\u00f3-Torrent\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara Eichau","family":"Madue\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Gasc\u00f3n-Gim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonaventura","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Mart\u00ednez-Y\u00e9lamos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta Aguado","family":"Valc\u00e1rcel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Luisa Mart\u00ednez","family":"Gin\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmina El Berdei","family":"Montero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Mar\u00eda L\u00f3pez","family":"Real","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Gonz\u00e1lez-Quintanilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Lopez","family":"de Silanes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Enrique","family":"Mart\u00ednez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucienne","family":"Costa-Frossard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mois\u00e9s Garc\u00e9s","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s Labiano","family":"Fontcuberta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Castellanos-Pinedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Antonio Garc\u00eda","family":"Merino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen Mu\u00f1oz","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Castillo-Trivi\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Meca-Lallana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaqu\u00edn Pe\u00f1a","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Rodr\u00edguez-Antig\u00fcedad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda Prieto","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo Ag\u00fcera","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada P\u00e9rez","family":"Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dulce M. Solar","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicol\u00e1s Herrera","family":"Varo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta Aguirre","family":"V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Manuel Rodr\u00edguez","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"R\u00edo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"12592_CR1","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1186\/s12913-017-2807-x","volume":"17","author":"A Sicras-Mainar","year":"2017","unstructured":"Sicras-Mainar A, Ru\u00edz-Beato E, Navarro-Artieda R, Maurino J. Impact on healthcare resource utilization of multiple sclerosis in Spain. BMC Health Serv Res. 2017;17:854. https:\/\/doi.org\/10.1186\/s12913-017-2807-x.","journal-title":"BMC Health Serv Res"},{"key":"12592_CR2","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1177\/1352458517694432","volume":"23","author":"G Kobelt","year":"2017","unstructured":"Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23:1123\u201336. https:\/\/doi.org\/10.1177\/1352458517694432.","journal-title":"Mult Scler"},{"key":"12592_CR3","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1177\/1352458517708672","volume":"23","author":"C Oreja-Guevara","year":"2017","unstructured":"Oreja-Guevara C, Kobelt G, Berg J, Capsa D, Eriksson J. New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain. Mult Scler. 2017;23:166\u201378. https:\/\/doi.org\/10.1177\/1352458517708672.","journal-title":"Mult Scler"},{"key":"12592_CR4","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1177\/1352458506069540","volume":"13","author":"B Ares","year":"2007","unstructured":"Ares B, Prieto JM, Lema M, Dapena D, Arias M, Noya M. Prevalence of multiple sclerosis in Santiago de Compostela (Galicia, Spain). Mult Scler. 2007;13:262\u20134. https:\/\/doi.org\/10.1177\/1352458506069540.","journal-title":"Mult Scler"},{"key":"12592_CR5","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.nrl.2014.04.016","volume":"30","author":"M B\u00e1rtulos Iglesias","year":"2015","unstructured":"B\u00e1rtulos Iglesias M, Marzo Sola ME, Estrella Ruiz LA, Bravo AY. Epidemiological study of multiple sclerosis in La Rioja. Neurologia. 2015;30:552\u201360. https:\/\/doi.org\/10.1016\/j.nrl.2014.04.016.","journal-title":"Neurologia"},{"key":"12592_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/ane.12363","volume":"132","author":"G Izquierdo","year":"2015","unstructured":"Izquierdo G, Venegas A, Sanabria C, Navarro G. Long-term epidemiology of multiple sclerosis in the Northern Seville District. Acta Neurol Scand. 2015;132:111\u20137. https:\/\/doi.org\/10.1111\/ane.12363.","journal-title":"Acta Neurol Scand"},{"key":"12592_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.msard.2016.06.003","volume":"9","author":"A Candeliere-Merlicco","year":"2016","unstructured":"Candeliere-Merlicco A, Valero-Delgado F, Mart\u00ednez-Vidal S, Lastres-Arias MC, Aparicio-Castro E, Toledo-Romero F, et al. Prevalence of multiple sclerosis in Health District III, Murcia, Spain. Mult Scler Relat Disord. 2016;9:31\u20135. https:\/\/doi.org\/10.1016\/j.msard.2016.06.003.","journal-title":"Mult Scler Relat Disord"},{"key":"12592_CR8","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/brain\/awq076","volume":"133","author":"E Leray","year":"2010","unstructured":"Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger J, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010;133:1900\u201313. https:\/\/doi.org\/10.1093\/brain\/awq076.","journal-title":"Brain"},{"key":"12592_CR9","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1177\/1352458519848090","volume":"26","author":"K Ahrweiller","year":"2020","unstructured":"Ahrweiller K, Rousseau C, Le Page E, Bajeux E, Leray E, Michel L, et al. Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis. Mult Scler. 2020;26:924\u201335. https:\/\/doi.org\/10.1177\/1352458519848090.","journal-title":"Mult Scler"},{"key":"12592_CR10","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1177\/13524585070130030101","volume":"13","author":"AG Beiske","year":"2007","unstructured":"Beiske AG, Naess H, Aarseth JH, Andersen O, Elovaara I, Farkkila M, et al. Health-related quality of life in secondary progressive multiple sclerosis. Mult Scler. 2007;13:386\u201392. https:\/\/doi.org\/10.1177\/13524585070130030101.","journal-title":"Mult Scler"},{"key":"12592_CR11","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1093\/brain\/aww173","volume":"139","author":"J Lorscheider","year":"2016","unstructured":"Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D, et al. Defining secondary progressive multiple sclerosis. Brain. 2016;139:2395\u2013405. https:\/\/doi.org\/10.1093\/brain\/aww173.","journal-title":"Brain"},{"key":"12592_CR12","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1080\/03007995.2021.1904860","volume":"37","author":"J Chataway","year":"2021","unstructured":"Chataway J, Murphy N, Khurana V, Schofield H, Findlay J, Adlard N. Secondary progressive multiple sclerosis: a systematic review of costs and health state utilities. Curr Med Res Opin. 2021;37:995\u20131004. https:\/\/doi.org\/10.1080\/03007995.2021.1904860.","journal-title":"Curr Med Res Opin"},{"key":"12592_CR13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1080\/13696998.2019.1682004","volume":"23","author":"T Purmonen","year":"2020","unstructured":"Purmonen T, Hakkarainen T, Tervomaa M, Ruutiainen J. Impact of multiple sclerosis phenotypes on burden of disease in Finland. J Med Econ. 2020;23:156\u201365. https:\/\/doi.org\/10.1080\/13696998.2019.1682004.","journal-title":"J Med Econ"},{"key":"12592_CR14","doi-asserted-by":"publisher","first-page":"205521731985838","DOI":"10.1177\/2055217319858383","volume":"5","author":"H Gyllensten","year":"2019","unstructured":"Gyllensten H, Kavaliunas A, Murley C, Alexanderson K, Hillert J, Tingh\u00f6g P, et al. Costs of illness progression for different multiple sclerosis phenotypes: a population-based study in Sweden. Mult Scler J Exp Transl Clin. 2019;5:2055217319858383. https:\/\/doi.org\/10.1177\/2055217319858383.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"12592_CR15","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1177\/1352458517737388","volume":"24","author":"M Tinelli","year":"2018","unstructured":"Tinelli M, Kanavos P, Efthymiadou O, Visintin E, Grimaccia F, Mossman J. Using IMPrESS to guide policy change in multiple sclerosis. Mult Scler. 2018;24:1251\u20135. https:\/\/doi.org\/10.1177\/1352458517737388.","journal-title":"Mult Scler"},{"key":"12592_CR16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/14737167.2017.1358617","volume":"17","author":"O Fern\u00e1ndez","year":"2017","unstructured":"Fern\u00e1ndez O, Calleja-Hern\u00e1ndez MA, Meca-Lallana J, Oreja-Guevara C, Polanco A, P\u00e9rez-Alc\u00e1ntara F. Estimate of the cost of multiple sclerosis in Spain by literature review. Expert Rev Pharmacoecon Outcomes Res. 2017;17:321\u201333. https:\/\/doi.org\/10.1080\/14737167.2017.1358617.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"12592_CR17","unstructured":"Comit\u00e9 Asesor para la Financiaci\u00f3n de la Prestaci\u00f3n Farmac\u00e9utica del Sistema Nacional de Salud. Gu\u00eda de Evaluaci\u00f3n Econ\u00f3mica de Medicamentos https:\/\/www.sanidad.gob.es\/areas\/farmacia\/comitesAdscritos\/prestacionFarmaceutica\/docs\/20240227_CAPF_Guia_EE_definitiva.pdf. Accessed 12 Nov 2024."},{"key":"12592_CR18","unstructured":"Base de datos eSalud. Informaci\u00f3n econ\u00f3mica del sector sanitario. http:\/\/esalud.oblikue.com\/. Accessed 6 Sept 2019."},{"key":"12592_CR19","unstructured":"General Pharmaceutical Council of Spain. BOT Plus 2.0. Base de datos de medicamentos. https:\/\/botplusweb.portalfarma.com\/. Accessed 14 Nov 2021."},{"key":"12592_CR20","unstructured":"Garc\u00e9s M, Crespo Puras MdC, Finkel Morgenstern L, Arroyo Men\u00e9ndez M. Estudio sobre las enfermedades neurodegenerativas en Espa\u00f1a y su impacto econ\u00f3mico y social. https:\/\/neuroalianza.org\/wp-content\/uploads\/Informe-NeuroAlianza-Completo-v-5-optimizado.pdf. Accessed 14 Nov 2021."},{"key":"12592_CR21","unstructured":"Instituto Nacional de Estad\u00edstica (INE). INEbase. https:\/\/www.ine.es\/. Accessed 6 Sept 2019."},{"key":"12592_CR22","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jval.2016.02.020","volume":"19","author":"L Vallejo-Torres","year":"2016","unstructured":"Vallejo-Torres L, Garc\u00eda-Lorenzo B, Castilla I, Valc\u00e1rcel-Nazco C, Garc\u00eda-P\u00e9rez L, Linertov\u00e1 R, et al. On the estimation of the cost-effectiveness threshold: Why, What, How? Value Health. 2016;19:558\u201366. https:\/\/doi.org\/10.1016\/j.jval.2016.02.020.","journal-title":"Value Health"},{"issue":"Suppl 1","key":"12592_CR23","doi-asserted-by":"publisher","first-page":"i89","DOI":"10.1136\/ard.2009.117150","volume":"69","author":"WB van den Hout","year":"2010","unstructured":"van den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis. 2010;69(Suppl 1):i89\u201391. https:\/\/doi.org\/10.1136\/ard.2009.117150.","journal-title":"Ann Rheum Dis"},{"key":"12592_CR24","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1136\/jnnp.73.6.701","volume":"73","author":"A Riazi","year":"2002","unstructured":"Riazi A, Hobart JC, Lamping DL, Fitzpatrick R, Thompson AJ. Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples. J Neurol Neurosurg Psychiatry. 2002;73:701\u20134. https:\/\/doi.org\/10.1136\/jnnp.73.6.701.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl 1","key":"12592_CR25","first-page":"79","volume":"112","author":"X Badia","year":"1999","unstructured":"Badia X, Roset M, Montserrat S, Herdman M, Segura A. The Spanish version of EuroQol: a description and its applications. European Quality of Life scale. Med Clin (Barc). 1999;112(Suppl 1):79\u201385.","journal-title":"Med Clin (Barc)."},{"issue":"Suppl 1","key":"12592_CR26","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1093\/clinids\/18.supplement_1.s79","volume":"18","author":"JD Fisk","year":"1994","unstructured":"Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis. 1994;18(Suppl 1):S79\u201383. https:\/\/doi.org\/10.1093\/clinids\/18.supplement_1.s79.","journal-title":"Clin Infect Dis"},{"key":"12592_CR27","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1177\/1352458517690821","volume":"23","author":"RH Benedict","year":"2017","unstructured":"Benedict RH, DeLuca J, Phillips G, LaRocca N, Hudson LD, Rudick R. Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. Mult Scler. 2017;23:721\u201333. https:\/\/doi.org\/10.1177\/1352458517690821.","journal-title":"Mult Scler"},{"key":"12592_CR28","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1034\/j.1600-0447.2003.00062.x","volume":"107","author":"JM Quintana","year":"2003","unstructured":"Quintana JM, Padierna A, Esteban C, Arostegui I, Bilbao A, Ruiz I. Evaluation of the psychometric characteristics of the Spanish version of the Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 2003;107:216\u201321. https:\/\/doi.org\/10.1034\/j.1600-0447.2003.00062.x.","journal-title":"Acta Psychiatr Scand"},{"key":"12592_CR29","doi-asserted-by":"publisher","first-page":"e0222929","DOI":"10.1371\/journal.pone.0222929","volume":"14","author":"MP Amato","year":"2019","unstructured":"Amato MP, Prestipino E, Bellinvia A, Niccolai C, Razzolini L, Past\u00f2 L, et al. Cognitive impairment in multiple sclerosis: an exploratory analysis of environmental and lifestyle risk factors. PLoS One. 2019;14:e0222929. https:\/\/doi.org\/10.1371\/journal.pone.0222929.","journal-title":"PLoS One"},{"key":"12592_CR30","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s10072-018-3404-4","volume":"39","author":"C Piccinni","year":"2018","unstructured":"Piccinni C, Ronconi G, Calabria S, Dondi L, Forcesi E, Rossi E, et al. Healthcare resources utilisation in primary progressive multiple sclerosis. Neurol Sci. 2018;39:1169\u201374. https:\/\/doi.org\/10.1007\/s10072-018-3404-4.","journal-title":"Neurol Sci"},{"key":"12592_CR31","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1007\/s00415-020-10279-7","volume":"268","author":"CS Simonsen","year":"2021","unstructured":"Simonsen CS, Flemmen H, Broch L, Brunborg C, Berg-Hansen P, Moen SM, et al. The course of multiple sclerosis rewritten: a Norwegian population-based study on disease demographics and progression. J Neurol. 2021;268:1330\u201341. https:\/\/doi.org\/10.1007\/s00415-020-10279-7.","journal-title":"J Neurol"},{"key":"12592_CR32","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/13696998.2018.1427100","volume":"21","author":"P Carney","year":"2018","unstructured":"Carney P, O\u2019Boyle D, Larkin A, McGuigan C, O\u2019Rourke K. Societal costs of multiple sclerosis in Ireland. J Med Econ. 2018;21:425\u201337. https:\/\/doi.org\/10.1080\/13696998.2018.1427100.","journal-title":"J Med Econ"},{"key":"12592_CR33","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.rec.2013.12.014","volume":"67","author":"JF Delgado","year":"2014","unstructured":"Delgado JF, Oliva J, Llano M, Pascual-Figal D, Grillo JJ, Com\u00edn-Colet J, et al. Health care and nonhealth care costs in the treatment of patients with symptomatic chronic heart failure in Spain. Rev Esp Cardiol (Engl Ed). 2014;67:643\u201350. https:\/\/doi.org\/10.1016\/j.rec.2013.12.014.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"12592_CR34","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s10198-016-0799-9","volume":"18","author":"J Alvarez-Sab\u00edn","year":"2017","unstructured":"Alvarez-Sab\u00edn J, Quintana M, Masjuan J, Oliva-Moreno J, Mar J, Gonzalez-Rojas N, et al. Economic impact of patients admitted to stroke units in Spain. Eur J Health Econ. 2017;18:449\u201358. https:\/\/doi.org\/10.1007\/s10198-016-0799-9.","journal-title":"Eur J Health Econ"},{"key":"12592_CR35","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/j.1468-1331.2006.01342.x","volume":"13","author":"M Pugliatti","year":"2006","unstructured":"Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, V\u00e9csei L, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol. 2006;13:700\u201322. https:\/\/doi.org\/10.1111\/j.1468-1331.2006.01342.x.","journal-title":"Eur J Neurol"},{"key":"12592_CR36","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1136\/jnnp.2006.090365","volume":"77","author":"G Kobelt","year":"2006","unstructured":"Kobelt G, Berg J, Lindgren P, Fredrikson S, J\u00f6nsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2006;77:918\u201326. https:\/\/doi.org\/10.1136\/jnnp.2006.090365.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12592_CR37","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/ane.12630","volume":"135","author":"M Moccia","year":"2017","unstructured":"Moccia M, Palladino R, Lanzillo R, Triassi M, Brescia MV. Predictors of the 10-year direct costs for treating multiple sclerosis. Acta Neurol Scand. 2017;135:522\u20138. https:\/\/doi.org\/10.1111\/ane.12630.","journal-title":"Acta Neurol Scand"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12592-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-025-12592-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12592-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:43:53Z","timestamp":1744245833000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-025-12592-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12592"],"URL":"https:\/\/doi.org\/10.1186\/s12913-025-12592-1","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"2 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol, informed consent forms, and information for patients were approved by the Ethical and Clinical Research Committee of Principado de Asturias. Also, the study was conducted according to the guidelines of the Spanish Agency of Medicines and Medical Devices, with the post-marketing study code NOV-EMS-2019-01. Before being included in the study, participants were required to provide informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No individual data included in the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"COG has received speaker and consultation fees from: Alexion, Biogen Idec, Bristol-Myers-Squibb, Janssen, Merck, Novartis, Roche, Sanofi-Genzyme, and Teva. JEML has received grants or contracts from: Sanofi, Biogen, Novartis, Roche, Bristol Myers Squibb, Merck, Janssen, and Alexion; consulting fees from: Biogen, Sanofi, Bristol Myers Squibb, Merck, Janssen, and Alexion; payment or honoraria for lectures, presentations, speaker\u2019s bureaus, manuscript writing or educational events and Support for attending meetings and\/or travel from: Sanofi, Biogen, Novartis, Roche, Bristol Myers Squibb, Merck, and Janssen. MAHP has received payment or honoraria for lectures, presentations, speaker\u2019s bureaus, manuscript writing or educational events and support for attending meetings and\/or travel from: Biogen, Merck, Novartis, and Sanofi. JGG has received payment or honoraria for lectures, presentations, speaker\u2019s bureaus, manuscript writing or educational events from: Biogen, Merck, Sanofi, Roche, Teva, Janssen, and Novartis; payment for expert testimony from: Roche, and Sanofi; support for attending meetings and\/or travel from: Biogen, Merck, Sanofi, Roche, Teva, Janssen, Almirall, and Novartis; participation on a Data Safety Monitoring Board or Advisory Board: Sanofi. AMAT has received consulting fees from: Novartis, Biogen, Janssen, Roche, and Sanofi; payment or honoraria for lectures, presentations, speaker\u2019s bureaus, manuscript writing or educational events from: Merck, Sanofi, Janssen, Almirall, Roche, Novartis, Biogen, and BMS; support for attending meetings and\/or travel: Biogen. BPF has received speaker honoraria from: Novartis and Almirall; travel honoraria from: Merck and Sanofi; training honoraria from: Sanofi and Merck. LRT has received consulting fees from: BMS and Sanofi; payment or honoraria for lectures, presentations, speaker\u2019s bureaus, manuscript writing or educational events from: BMS, Sanofi, Novartis, Merck, Janssen, Biogen, and Horizon; support for attending meetings and\/or travel from: BMS, Sanofi, Novartis, Merck, Janssen, and Biogen. SEM has received speaker honoraria and consultant fees from: Janssen, Bristol-Meyers-Squibb, Biogen Idec, Novartis, Merck, Bayer, Sanofi Genzyme, Roche, and Teva. FGG has received funding for research grants, travel support and honoraria for speaking engagements from: Bayer, Biogen, Roche, Merck, Novartis, Almirall, Teva, Bristol-Meyers-Squibb, and Genzyme-Sanofi. BC has received grants for advisory boards from: Sanofi, Roche, Merck, Horizon, and Novartis. SMY has participated as Principal Investigator in clinical trials promoted by industry from: Roche, Sanofi, Biogen, Merck, and Novartis; support for attending meetings and\/or travel from: Biogen, BMS, Janssen, Merck, Novartis, Roche, and Sanofi. MAV has been consulting for: Novartis, Biogen, Sanofi, and Merck; payment or honoraria for lectures, presentations, speaker\u2019s bureaus, manuscript writing or educational events from: Novartis, Biogen, Sanofi, Merck, and Roche. Grants or contracts from: Novartis, Biogen, Sanofi, Merck, and Teva; support for attending meetings and\/or travel from: Novartis, Biogen, Sanofi, Merck, Teva, and Roche. MLMG has received compensation for consulting services and speaking fees from: Merck, Biogen, Novartis, Sanofi, Almirall, Roche, BMS, Janssen-Cilag, and Viatris. YEBM has received payment or honoraria for lectures, presentations, speaker\u2019s bureaus, manuscript writing or educational events from: Novartis, Roche, Sanofi-Genzyme, Almirall, Bayer, Merck, and Biogen. AMLR has acted as a speaker for Roche, Biogen Idec, Genzyme-Sanofi, Janssen, and Novartis. JEMR has participated as consultant and has received payment or honoraria for lectures, presentations, speaker\u2019s bureaus, manuscript writing or educational events from: Novartis, Biogen Idec, Sanofi, and Merck Serono. LCF has received honoraria for lecturing, travel expenses for attending meetings from: Merck, Bayer, Biogen, Novartis, Sanofi Genzyme, Almirall, Roche, Celgene, Biopas, Ipsen, and Teva. MGR has received honoraria as a lecturer from: Sanofi-Aventis, Novartis, Biogen, and Merck. TCT has received speaking\/consulting fees and\/or travel funding from: Almirall, Biogen, Bristol-Myers-Squibb, Janssen, Merck, Novartis, Roche, Sanofi Genzyme, and Teva. VML has received consulting or speaking fees from: Almirall, Biogen, Genzyme, Janssen, Merck Serono, Novartis, Roche, Terumo, Sanofi, Teva, Celgene, and Bristol-Myers-Squibb. JPM has received speaker and consultation fees and congress travel support from: Biogen, Bristol-Myers-Squibb, Janssen, Merck, Novartis, Roche, and Sanofi. ARA has participated as a medical adviser\/speaker for: Merck, Biogen, Novartis, Roche, Sanofi, Sandoz, Teva, and Bristol-Myers-Squibb. JMPG has been a consultant for Bayer Pharmaceuticals, Biogen Spain S.L., Daiichi Sankyo Spain, Genzyme Corporation, Janssen Spain, Merck Serono, Novartis Pharmaceuticals Corporation, Sanofi, Sandoz Iberia, Teva Pharmaceutical Industries, Roche Pharma, Almirall Prodesfarma S.A., and Celgene Spain S.L. He has participated as a speaker\/moderator in meetings and\/or symposiums organized by Almirall Prodesfarma S.A., Bayer Pharmaceuticals, Biogen Spain S.L., Genzyme Corporation, Merck Serono, Novartis Pharmaceuticals Corporation, Sanofi, Teva Pharmaceutical Industries, and Roche Pharma. EAM has received speaker honoraria from: Roche, Novartis, Merck, Sanofi, and Biogen. IPM has received payment or honoraria for lectures, presentations, speaker\u2019s bureaus, manuscript writing or educational events from: Novartis. DMSS has participated as a medical adviser\/speaker for Biogen, Novartis, Sanofi, Almirall, Roche, Merck, and Bristol-Myers-Squibb. MAV and JMRB are Novartis employees. JR has received speaking honoraria and support for attending meetings and\/or travel in advisory boards from: Biogen-Idec, Genzyme, Merck-Serono, Novartis, Teva, Roche, Janssen, and Sanofi-Aventis. IGE, JRA, VGQ, ALF, FCP, JAGM, CMF and NHV: no disclosures reported.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"525"}}